Grutters, J.C.

patient treatment heterogeneity patient heterogeneity value decision health organ sarcoidosi evaluation parameter-speci fic evic analysis study infliximab population group extrapulmonary article effect outcome method result cost-effectiveness 15-3 cancer muc 1 568 parameter breast attribute policy parameter-speci table level model epost university research preference subgroup subgroups 15-3 levels baseline treatment decision patient-level example framework disease score cost-effectiveness analysis input parameters involvement uncertainty paper extrapulmonary sarcoidosis /g polymorphism evic framework author regression breast cancer patient-level attributes placebo analyses subgroup policy strati fied analyses calculation source impact sculpher input number severity breast cancer patients population reimbursement decisions ef ficiency infliximab groups baseline risk difference trial state characteristic